VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
THC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
THCTenet Healthcare Corporation
$262.06$22.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. THC
  4. Financial Ratios

Tenet Healthcare Corporation (THC) Financial Ratios

Latest Ratios: P/E Ratio 16.6x · EV/EBITDA 7.5x · ROE 16.1%. (1995–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

THC Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$22.1B$18.1B$12.4B$7.9B$5.4B$8.9B$4.2B$3.9B$1.8B$1.5B$1.5B
Enterprise Value$32.4B$28.3B$23.7B$21.7B$19.6B$22.2B$17.5B$18.4B$16.2B$15.9B$16.0B
P/E Ratio →16.5612.833.8613.2312.879.7010.65—16.02——
P/S Ratio1.040.850.600.390.280.460.240.210.100.080.08
P/B Ratio2.602.011.451.441.172.081.471.980.850.630.42
P/FCF8.737.1311.074.8816.809.751.486.984.123.09—
P/OCF6.245.106.043.344.985.661.253.191.701.272.64

P/E links to full P/E history page with 30-year chart

THC EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—1.331.151.061.021.140.991.000.880.830.82
EV / EBITDA7.536.593.496.426.185.956.157.726.647.997.64
EV / EBIT9.417.833.908.628.787.8810.4614.129.9217.1013.05
EV / FCF—11.2021.2013.3761.1024.346.1132.7237.4932.15—

THC Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin82.3%82.3%39.7%38.0%36.8%37.3%35.3%36.3%36.4%35.4%36.4%
Operating Margin16.1%16.1%28.8%12.2%12.2%14.7%11.3%8.3%8.9%5.8%6.4%
Net Profit Margin6.6%6.6%15.5%3.0%2.1%4.7%2.3%-1.2%0.6%-3.7%-1.0%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE16.1%16.1%45.5%12.1%9.3%25.6%16.4%-10.5%4.6%-23.9%-5.7%
ROA4.8%4.8%11.2%2.2%1.5%3.3%1.6%-0.9%0.5%-2.9%-0.8%
ROIC13.2%13.2%22.8%9.9%9.6%12.8%9.1%7.0%7.4%4.8%5.3%
ROCE13.8%13.8%24.7%10.9%10.3%12.8%9.6%8.2%8.7%5.6%6.2%

THC Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity1.471.471.682.723.273.685.447.427.046.214.39
Debt / EBITDA3.063.062.114.444.754.205.526.186.087.537.27
Net Debt / Equity—1.151.322.503.093.124.597.286.845.964.18
Net Debt / EBITDA2.392.391.674.084.483.564.666.075.917.226.93
Debt / FCF—4.0710.138.4944.3014.604.6325.7433.3729.06—
Interest Coverage4.414.417.352.792.513.051.671.321.630.901.25

THC Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio1.761.761.781.511.341.381.471.211.201.291.30
Quick Ratio1.681.681.701.421.251.311.401.131.121.221.22
Cash Ratio0.650.650.700.260.190.460.500.060.110.140.18
Asset Turnover—0.720.710.730.710.710.650.790.820.820.79
Inventory Turnover10.8610.8636.0031.0029.9431.8231.0037.9538.2142.8538.28
Days Sales Outstanding—43.9353.9460.4765.9061.9369.3464.4761.6557.5763.84

THC Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield6.0%7.8%25.9%7.6%7.8%10.3%9.4%—6.2%——
FCF Yield11.5%14.0%9.0%20.5%6.0%10.3%67.6%14.3%24.3%32.3%—
Buyback Yield6.5%8.0%5.4%2.5%4.6%0.0%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield6.5%8.0%5.4%2.5%4.6%0.0%0.0%0.0%0.0%0.0%0.0%
Shares Outstanding—$91M$98M$105M$111M$109M$106M$103M$104M$101M$99M

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrong
Balance SheetAdequate
Cash FlowImproving
Top Statement Risk

USPI concentration and revenue deferrals

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Margin Expansion Driven by Mix Shift

Operating margin improved to 18.2% in Q2 2026 from 15.6% a year earlier, per reported financials, reflecting the higher-margin ambulatory mix and disciplined cost control.

The sequential improvement in operating margin from 16.4% in Q1 2026 to 18.2% in Q2 2026 suggests that the shift toward USPI and higher-acuity services is translating into bottom-line leverage. However, the gross margin volatility—swinging from 82.3% in Q2 2025 to 18.2% in Q2 2026—indicates that the reported gross margin is not a reliable indicator of core profitability, as it likely excludes labor costs. Investors should focus on operating margin as the more stable measure of earning power, given the fixed-cost nature of hospital operations.

ROIC Recovery Signals Value Creation

ROIC improved to 4.0% in Q2 2026 from 3.2% in Q2 2024, per financial statements, suggesting that capital deployed into USPI is beginning to generate higher returns.

The upward trend in ROIC, albeit from a low base, indicates that management's portfolio reshaping toward ambulatory care is gradually improving capital efficiency. The spike in Q1 2024 (13.2%) was likely distorted by one-time gains, as subsequent quarters normalized to the 3-4% range. This suggests that the company is still in the early stages of compounding returns, and investors should monitor whether ROIC can sustain above 5% as the mix shift matures.

Working Capital Efficiency Improves

Cash conversion cycle turned negative to -39 days in Q2 2025, per reported data, reflecting favorable payment terms and efficient receivables management, though it has since normalized to 22 days.

The negative CCC in early 2025 was driven by a sharp increase in DPO to 131 days, which appears to be a timing anomaly rather than a sustainable trend, as DPO has since reverted to 27 days. DSO has improved from 62 days in Q2 2024 to 42 days in Q2 2026, indicating better collections, possibly due to a higher mix of managed care and government payers. Asset turnover remains low at 0.18, consistent with the capital-intensive hospital business, but the improvement in working capital metrics suggests operational discipline.

Leverage Elevated but Deleveraging Underway

Debt-to-EBITDA declined to 10.69 in Q2 2026 from 13.28 in Q2 2024, per reported figures, while interest coverage improved to 5.02, indicating gradually easing debt service burden.

Despite the high absolute leverage, the trend is favorable: D/E has fallen from 1.68 to 1.52 over the same period, and interest coverage has risen from 3.89 to 5.02. This suggests that EBITDA growth is outpacing debt growth, likely due to margin expansion and disciplined capital allocation. However, the D/EBITDA ratio remains elevated relative to peers like HCA (8.85), indicating that Tenet still carries a heavier debt load, which could constrain financial flexibility in a rising rate environment.

Liquidity Buffer Adequate but Thin

Current ratio improved to 1.41 in Q2 2026 from 1.44 in Q1 2024, per balance sheet data, with cash of $2.2B providing a modest cushion against short-term obligations.

The quick ratio of 1.35 indicates that inventory is not a significant liquidity concern, which is typical for a services business. However, the current ratio is only slightly above 1, suggesting that the company relies on ongoing cash flows to meet near-term liabilities. Under a severe stress scenario—such as a prolonged downturn in elective procedures—the liquidity position could become strained, especially given the high fixed-cost structure and debt service requirements.

Misapplied EV/EBITDA Multiple

EV/EBITDA of 8.01 appears cheap, but it understates Tenet's true leverage and the drag from non-controlling interests, per reported financials, warranting a sum-of-the-parts approach.

The EV/EBITDA multiple is commonly used to compare hospital operators, but for Tenet it is misleading because a significant portion of EBITDA is generated by USPI, where non-controlling physician partners own a stake. This means that consolidated EBITDA overstates the cash flow available to Tenet shareholders. Additionally, the high debt load inflates EV, making the multiple appear artificially low. Investors should instead use EV/EBITDAR or a sum-of-the-parts valuation that assigns a higher multiple to the USPI segment and a lower one to the hospital operations, as the market may be applying a conglomerate discount.

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

Consensus & Technical Research Suite
Open THC Terminal

THC Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

THC — Frequently Asked Questions

Quick answers to the most common questions about buying THC stock.

What is Tenet Healthcare Corporation's P/E ratio?

Tenet Healthcare Corporation's current P/E ratio is 16.6x. The historical average is 18.7x. This places it at the 61th percentile of its historical range.

What is Tenet Healthcare Corporation's EV/EBITDA?

Tenet Healthcare Corporation's current EV/EBITDA is 7.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 7.7x.

What is Tenet Healthcare Corporation's ROE?

Tenet Healthcare Corporation's return on equity (ROE) is 16.1%. The historical average is -0.9%.

Is THC stock overvalued?

Based on historical data, Tenet Healthcare Corporation is trading at a P/E of 16.6x. This is at the 61th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Tenet Healthcare Corporation's profit margins?

Tenet Healthcare Corporation has 82.3% gross margin and 16.1% operating margin. Operating margin between 10-20% is typical for established companies.

How much debt does Tenet Healthcare Corporation have?

Tenet Healthcare Corporation's Debt/EBITDA ratio is 3.1x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.